Polatuzumab vedotin clinical trials
9 indexed studies · 3 currently recruiting
- Active not recruitingPHASE2
Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP
This study is testing a new combination of medicines for older or less fit patients with a type of aggressive B-cell lymphoma who haven't had treatment before. The aim is to see if this new approach, called R-Pola-Glo, is safe and effective.
For: Lymphoma, Large B-Cell, DiffuseAustria · Germany - Active not recruitingPHASE3
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
This study is looking at a new treatment called glofitamab for a type of cancer called large B-cell lymphoma. It compares this new treatment, along with other medicines, against a standard treatment for people who haven't had treatment before.
For: Large B-Cell LymphomaUnited States · Argentina · Australia - Active not recruitingPHASE1, PHASE2
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
This study looks at new drug combinations for adults with a type of blood cancer called Non-Hodgkin's Lymphoma that has come back or not responded to previous treatments. It aims to find the safest dose and see how well these new treatments work.
For: Non-Hodgkins LymphomaBelgium · Denmark · Israel - Active not recruitingPHASE1, PHASE2
A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
This study looks at new drug combinations to treat B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma. We want to see how safe and effective these new treatments are, especially when other treatments haven't worked.
For: B-cell Non-Hodgkin LymphomaUnited States · Belgium · Canada - RecruitingPHASE2
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
This study looks at a new drug, epcoritamab, combined with other cancer medicines, for adults with Non-Hodgkin Lymphoma. It aims to see how safe these combinations are and if they help reduce the disease. Epcoritamab is given as an injection under the skin.
For: Non-Hodgkin LymphomaUnited States · China · Czechia - RecruitingPHASE2
A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma
This study looks at new drug combinations for large B-cell lymphoma that has come back or not responded to past treatments. It checks how safe and effective these drugs are, both before and after a treatment called CAR-T cell therapy.
For: Large B-cell LymphomaUnited Kingdom - Active not recruitingPHASE1
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
This study is testing new combinations of anti-cancer medicines for people with B-cell non-Hodgkin lymphoma that has come back or not responded to previous treatments. It aims to find safe doses and see how well these new combinations work.
For: B-Cell Non-Hodgkin Lymphoma · Relapsed B-Cell Non-Hodgkin Lymphoma · Refractory B-Cell Non-Hodgkin LymphomaUnited States · Belgium · Czechia - RecruitingPHASE2
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
This study compares two treatments for a fast-growing blood cancer called diffuse large B-cell lymphoma (DLBCL), specifically a type called GCB DLBCL. Researchers want to see if a new drug, zilovertamab vedotin, when combined with standard therapy, works better than another combination in shrinking the cancer.
For: Lymphoma, Large B-Cell, DiffuseUnited States · Belgium · Germany - Active not recruitingPHASE3
Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)
This study compares two treatments for a type of blood cancer called Diffuse Large B-cell Lymphoma (DLBCL) that has come back or not responded well to initial treatment. One treatment is a standard chemotherapy, and the other adds a new drug, polatuzumab vedotin, to that standard treatment.
For: Relapsed Diffuse Large B-cell Lymphoma · Refractory Diffuse Large B-Cell LymphomaAustria · Germany · Spain